In primary T cells, TNFRSF25 agonists enhance survival ... the addition of anti-TNFRSF25 agonist antibody enhanced antitumor responses (Fig. 1). Notably, in a B16-F10 melanoma model, in which ...

A team has identified a previously unknown phase of the immune response. The results challenge long-standing assumptions about the process called 'T-cell priming'. These new insights have significant ...

A fine balance is needed for T reg cells to enable immune responses to pathogens without ... monoclonal antibody manifesting enhanced antitumor immunity. Beyond exhaustion, CD8 + T cells can ...

However, variability in efficacy and side effects has driven research into third-generation CAR T cells, which integrate two costimulatory domains to enhance the antitumor response. Clinical ...

The GPC3-CAR T cells were found to be safe, with peak cell expansion at two-weeks post-infusion; however, no objective ...

Harnessing immunosuppressive tumour microenvironment for a durable response in solid tumours While CAR T-cell therapy has revolutionised ... from phagocytosis and demonstrated synergistic anti-tumour ...

They observed that factors secreted by T cells boosted CTL function ... These results suggest that IL-3-activated basophils play a role in enhancing CTL antitumor responses. “This was not what I ...

To assess whether NK cells were involved in antitumor response generated by fasting ... in adoptive NK cell therapy at the MD Anderson Cancer Center, who wasn’t involved in the study. A fasting-based ...

Previous work by the team had shown that the NOTCH signaling pathway played a central role in differentiation, which is essential for an effective immune response by CD8 + T cells. In the new ...

“The use of NKT cells as effectors in allogeneic CAR-T therapy represents a promising strategy, offering not only direct cytotoxicity but also indirect anti-tumour activity through the priming ...

Chimeric antigen receptor (CAR) T cell therapy is an immunotherapy. It uses a patient’s own immune system to fight certain blood cancers. Normal T cells can “hook” onto cancer cells and kill them, but ...